Welcome to our dedicated page for Intensity Therapeutics news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on Intensity Therapeutics stock.
Intensity Therapeutics, Inc. (Nasdaq: INTS) is a Connecticut-based, clinical-stage biotechnology company pioneering new immune-based therapies to treat solid tumor cancers. Utilizing its proprietary DfuseRx℠ technology platform, Intensity Therapeutics develops unique drug formulations designed for direct intratumoral injection. These formulations disperse rapidly throughout a tumor, diffusing therapeutic agents into cancer cells to induce an adaptive systemic immune response. This innovative approach not only targets the injected tumors but also non-injected tumors, offering significant potential for cancer treatment.
The company's flagship candidate, INT230-6, is an investigational product composed of two potent anti-cancer agents, cisplatin and vinblastine, combined with a penetration enhancer molecule (SHAO). This combination allows the drug to saturate tumors, promoting local disease control and systemic anti-tumor effects without the immunosuppression often seen with systemic chemotherapy.
Intensity's product pipeline is robust, with a strong focus on the development and clinical testing of INT230-6. The company has completed enrollment for its Phase 1/2 clinical trial (IT-01), showcasing extended survival in refractory soft tissue sarcoma patients. The ongoing and planned trials include:
- Phase 3 study (INVINCIBLE-3) in soft tissue sarcoma, expected to start mid-2024, which will compare INT230-6 as a monotherapy against standard of care drugs.
- Phase 2/3 program (INVINCIBLE-4) in presurgical breast cancer, anticipated to initiate in mid-2024, evaluating INT230-6 combined with standard of care.
Additionally, INT230-6 is being explored in combination therapies through collaborations with major pharmaceutical companies, including Merck and Bristol-Myers Squibb, to evaluate its effectiveness with KEYTRUDA® (pembrolizumab) and ipilimumab, respectively.
Intensity Therapeutics has received multiple platform validations and support, demonstrated by its FDA orphan-drug designation for soft tissue sarcoma treatment and its successful upsized IPO in July 2023. The company continues to advance its mission, with a strong financial position and sufficient cash reserves expected to fund operations into 2025.
For more information about Intensity Therapeutics and its groundbreaking approach to cancer treatment, visit www.intensitytherapeutics.com and follow them on Twitter @IntensityInc.
Intensity Therapeutics (INTS) and SAKK presented Phase 2 data from the INVINCIBLE-2 study and provided updates on the ongoing INVINCIBLE-4 trial at the 2024 San Antonio Breast Cancer Symposium. The INVINCIBLE-4 study is a randomized trial evaluating INT230-6 in early-stage Triple Negative Breast Cancer (TNBC) patients, comparing standard of care (SOC) plus INT230-6 versus SOC alone. The trial aims to enroll 54 patients across seven Swiss sites.
The completed INVINCIBLE-2 study demonstrated that INT230-6 achieved >95% tumor killing in some patients with a single dose, with 74% of subjects showing significant necrosis in tumors larger than 2cm. The treatment showed favorable safety profiles and increased immune system activation, including enhanced T-cell and NK cell presence within tumors.
Intensity Therapeutics (INTS) has announced a $3 million registered direct offering and concurrent private placement. The company will issue 1,237,113 shares of common stock at $2.425 per share in a registered direct offering, along with warrants to purchase an equal number of shares at $2.95 per share in a private placement. The warrants will be exercisable after six months and expire in 5.5 years. The proceeds will be used for general working capital. A.G.P./Alliance Global Partners is leading the placement, with Brookline Capital Markets as co-placement agent. The offerings are expected to close around November 22, 2024.
Intensity Therapeutics (INTS) presented Phase 1/2 data for INT230-6 in sarcoma patients and provided an overview of its ongoing Phase 3 INVINCIBLE-3 Study. The Phase 1/2 trial showed a median overall survival of 21.3 months versus 6.7 months in the control group, with increased T-cell activation and favorable safety profile. The global Phase 3 study aims to enroll 333 patients with various sarcoma types across multiple countries. Key Phase 1/2 results included a 93.3% disease control rate at 2 months and 27% of patients showing shrinkage in uninjected tumors. The drug demonstrated good tolerability with only 20% of subjects experiencing Grade 3 adverse events.
Intensity Therapeutics (INTS) reports Q3 2024 financial results and provides updates on two clinical trials. The company's net loss increased to $3.5 million from $2.3 million year-over-year. R&D expenses rose to $2.2 million from $1.4 million, while G&A expenses increased to $1.4 million from $1.1 million. Cash position stands at $2.8 million, expected to fund operations into Q1 2025.
The company achieved regulatory authorizations in multiple countries for its Phase 3 INVINCIBLE-3 study in soft tissue sarcoma and Phase 2 INVINCIBLE-4 study in triple-negative breast cancer. The first patient was dosed in the INVINCIBLE-4 study in October 2024.
Intensity Therapeutics (Nasdaq: INTS) announced its selection for an oral podium presentation at the 2024 Connective Tissue Oncology Society (CTOS) meeting. Dr. Christian F. Meyer will present the completed Phase 2 results and the INVINCIBLE-3 Phase 3 randomized soft tissue sarcoma trial design on November 16, 2024, in San Diego. The presentation will focus on their intratumoral INT230-6 treatment compared to standard care therapy in metastatic soft tissue sarcomas. The study involves a combination of SHAO, vinblastine, and cisplatin as treatment components.
Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research SAKK announce the first patient dosed in their Phase 2 INVINCIBLE-4 clinical trial. The study evaluates INT230-6 combined with standard-of-care (SOC) versus SOC alone in treating triple-negative breast cancer (TNBC). The randomized trial will enroll approximately 54 patients in Switzerland and France, focusing on pathological complete response rates. Patients will receive either two doses of INT230-6 followed by SOC (pembrolizumab, anthracyclines, carboplatin, cyclophosphamide, and paclitaxel) or SOC alone. The initiation follows promising data from INVINCIBLE-2, where INT230-6 showed >95% tumor-killing properties with a single dose.
Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotechnology company, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. The event will be held at the Lotte New York Palace Hotel from September 9-11, 2024.
Lewis H. Bender, Founder, President and CEO, will deliver a corporate overview at 11:30 AM ET. The presentation will be available via live webcast and archived for approximately 90 days on the company's investor relations website. Joseph Talamo, CFO, will join Bender for one-on-one meetings throughout the conference.
Intensity Therapeutics focuses on developing novel immune-based intratumoral cancer therapies designed to kill tumors and enhance immune system recognition of cancers.
Intensity Therapeutics (INTS) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Initiated Phase 3 INVINCIBLE-3 Study for INT230-6 in soft tissue sarcoma, with first patient dosed.
2. Collaboration with SAKK for Phase 2 INVINCIBLE-4 Study in early-stage breast cancer.
3. Appointed Thomas Dubin to the board of directors.
4. Q2 2024 financials: R&D expenses $3.6M, G&A expenses $1.5M, net loss $5.0M.
5. Cash position of $6.3M, expected to fund operations into Q1 2025.
Intensity Therapeutics (Nasdaq: INTS) has announced the dosing of the first U.S. patient in its global Phase 3 study (INVINCIBLE-3) for metastatic soft tissue sarcoma using its lead product candidate, INT230-6, as a monotherapy. This trial will compare INT230-6 against standard-of-care chemotherapy in second and third-line treatments. The study will enroll approximately 333 patients across multiple countries. Phase 1/2 trials showed promising tumor-killing and immune-activating properties, with a median overall survival of 21.3 months. Regulatory filings for trial initiation have been submitted in Canada and Europe.
Intensity Therapeutics announced the appointment of Thomas Dubin to its Board of Directors, effective May 14, 2024. Dubin, who brings extensive experience in pharmaceutical business development, regulatory, and commercialization, will serve on the Audit Committee. This appointment expands the board from four to five directors, with four being independent. Dubin's background includes leadership roles at Alexion Pharmaceuticals, ChiRex, and various advisory positions. His expertise is expected to bolster Intensity Therapeutics as it advances into Phase 3 clinical trials for its cancer treatment, INT230-6.
FAQ
What is the current stock price of Intensity Therapeutics (INTS)?
What is the market cap of Intensity Therapeutics (INTS)?
What does Intensity Therapeutics, Inc. specialize in?
What is INT230-6?
What are the current clinical trials involving INT230-6?
Who are Intensity Therapeutics' notable collaborators?
What recent achievements has Intensity Therapeutics made?
What is the DfuseRx℠ technology platform?
What is the potential impact of INT230-6 on cancer treatment?
What financial condition is Intensity Therapeutics in?
What is the focus of the INVINCIBLE-3 study?